Cargando…
Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A
The clinical characteristics of B-cell lymphoma (BCL) were studied through the combined analysis of six clinical trials conducted by the Japan Clinical Oncology Group - Lymphoma Study Group (JCOG-LSG) for aggressive lymphoma in the 1990s, before the introduction of rituximab. Through a central patho...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JSLRT
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053572/ https://www.ncbi.nlm.nih.gov/pubmed/33731548 http://dx.doi.org/10.3960/jslrt.20062 |
_version_ | 1783680151116054528 |
---|---|
author | Kinoshita, Tomohiro Watanabe, Takashi Itoh, Kuniaki Yoshimura, Kenichi Tobinai, Kensei Ogura, Michinori Yamaguchi, Motoko Kurosawa, Mitsutoshi Imaizumi, Yoshitaka Ota, Shuichi Kaba, Harumi Mukai, Kiyoshi Nakamura, Shigeo Ohshima, Koichi Hotta, Tomomitsu Tsukasaki, Kunihiro Nagai, Hirokazu Shimoyama, Masanori |
author_facet | Kinoshita, Tomohiro Watanabe, Takashi Itoh, Kuniaki Yoshimura, Kenichi Tobinai, Kensei Ogura, Michinori Yamaguchi, Motoko Kurosawa, Mitsutoshi Imaizumi, Yoshitaka Ota, Shuichi Kaba, Harumi Mukai, Kiyoshi Nakamura, Shigeo Ohshima, Koichi Hotta, Tomomitsu Tsukasaki, Kunihiro Nagai, Hirokazu Shimoyama, Masanori |
author_sort | Kinoshita, Tomohiro |
collection | PubMed |
description | The clinical characteristics of B-cell lymphoma (BCL) were studied through the combined analysis of six clinical trials conducted by the Japan Clinical Oncology Group - Lymphoma Study Group (JCOG-LSG) for aggressive lymphoma in the 1990s, before the introduction of rituximab. Through a central pathological review, 829 patients were diagnosed with BCL according to the World Health Organization classification and treated with doxorubicin-containing combination chemotherapies. Of these patients, 642, 104, 30, and 24 patients were diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL), respectively. The overall survival (OS) of FL and MZL patients was higher than that of patients with DLBCL and MCL. The OS of the MCL patients was higher than that of DLBCL patients in the first 5 years, but MCL had the lowest survival after 5 years. The OS of DLBCL patients was clearly stratified by the international prognostic index and showed data compatible with that of aggressive lymphoma in the pre-rituximab era. These results established the clinical aspects of BCL in a large number of patients treated in prospective studies during the pre-rituximab era in Japan. |
format | Online Article Text |
id | pubmed-8053572 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | JSLRT |
record_format | MEDLINE/PubMed |
spelling | pubmed-80535722021-04-19 Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A Kinoshita, Tomohiro Watanabe, Takashi Itoh, Kuniaki Yoshimura, Kenichi Tobinai, Kensei Ogura, Michinori Yamaguchi, Motoko Kurosawa, Mitsutoshi Imaizumi, Yoshitaka Ota, Shuichi Kaba, Harumi Mukai, Kiyoshi Nakamura, Shigeo Ohshima, Koichi Hotta, Tomomitsu Tsukasaki, Kunihiro Nagai, Hirokazu Shimoyama, Masanori J Clin Exp Hematop Original Article The clinical characteristics of B-cell lymphoma (BCL) were studied through the combined analysis of six clinical trials conducted by the Japan Clinical Oncology Group - Lymphoma Study Group (JCOG-LSG) for aggressive lymphoma in the 1990s, before the introduction of rituximab. Through a central pathological review, 829 patients were diagnosed with BCL according to the World Health Organization classification and treated with doxorubicin-containing combination chemotherapies. Of these patients, 642, 104, 30, and 24 patients were diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL), respectively. The overall survival (OS) of FL and MZL patients was higher than that of patients with DLBCL and MCL. The OS of the MCL patients was higher than that of DLBCL patients in the first 5 years, but MCL had the lowest survival after 5 years. The OS of DLBCL patients was clearly stratified by the international prognostic index and showed data compatible with that of aggressive lymphoma in the pre-rituximab era. These results established the clinical aspects of BCL in a large number of patients treated in prospective studies during the pre-rituximab era in Japan. JSLRT 2021-03-18 /pmc/articles/PMC8053572/ /pubmed/33731548 http://dx.doi.org/10.3960/jslrt.20062 Text en © 2021 by The Japanese Society for Lymphoreticular Tissue Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License. |
spellingShingle | Original Article Kinoshita, Tomohiro Watanabe, Takashi Itoh, Kuniaki Yoshimura, Kenichi Tobinai, Kensei Ogura, Michinori Yamaguchi, Motoko Kurosawa, Mitsutoshi Imaizumi, Yoshitaka Ota, Shuichi Kaba, Harumi Mukai, Kiyoshi Nakamura, Shigeo Ohshima, Koichi Hotta, Tomomitsu Tsukasaki, Kunihiro Nagai, Hirokazu Shimoyama, Masanori Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study – JCOG0108A |
title | Clinical characteristics of patients with B-cell lymphoma enrolled in
clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma
Study Group study – JCOG0108A |
title_full | Clinical characteristics of patients with B-cell lymphoma enrolled in
clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma
Study Group study – JCOG0108A |
title_fullStr | Clinical characteristics of patients with B-cell lymphoma enrolled in
clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma
Study Group study – JCOG0108A |
title_full_unstemmed | Clinical characteristics of patients with B-cell lymphoma enrolled in
clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma
Study Group study – JCOG0108A |
title_short | Clinical characteristics of patients with B-cell lymphoma enrolled in
clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma
Study Group study – JCOG0108A |
title_sort | clinical characteristics of patients with b-cell lymphoma enrolled in
clinical trials for aggressive lymphoma in japan: japan clinical oncology group - lymphoma
study group study – jcog0108a |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053572/ https://www.ncbi.nlm.nih.gov/pubmed/33731548 http://dx.doi.org/10.3960/jslrt.20062 |
work_keys_str_mv | AT kinoshitatomohiro clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT watanabetakashi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT itohkuniaki clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT yoshimurakenichi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT tobinaikensei clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT oguramichinori clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT yamaguchimotoko clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT kurosawamitsutoshi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT imaizumiyoshitaka clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT otashuichi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT kabaharumi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT mukaikiyoshi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT nakamurashigeo clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT ohshimakoichi clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT hottatomomitsu clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT tsukasakikunihiro clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT nagaihirokazu clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a AT shimoyamamasanori clinicalcharacteristicsofpatientswithbcelllymphomaenrolledinclinicaltrialsforaggressivelymphomainjapanjapanclinicaloncologygrouplymphomastudygroupstudyjcog0108a |